- Home
- CLLS vs THRD Comparison
CLLS vs THRD Comparison
Compare CLLS & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- THRD
- Stock Information
- Founded
- CLLS 1999
- THRD 2019
- Country
- CLLS France
- THRD United States
- Employees
- CLLS N/A
- THRD N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- THRD Health Care
- Exchange
- CLLS Nasdaq
- THRD Nasdaq
- Market Cap
- CLLS 148.1M
- THRD 157.7M
- IPO Year
- CLLS 2007
- THRD 2022
- Fundamental
- Price
- CLLS $1.24
- THRD $3.50
- Analyst Decision
- CLLS Buy
- THRD Hold
- Analyst Count
- CLLS 3
- THRD 3
- Target Price
- CLLS $7.00
- THRD $5.00
- AVG Volume (30 Days)
- CLLS 836.8K
- THRD 339.6K
- Earning Date
- CLLS 03-13-2025
- THRD 03-27-2025
- Dividend Yield
- CLLS N/A
- THRD N/A
- EPS Growth
- CLLS N/A
- THRD N/A
- EPS
- CLLS N/A
- THRD N/A
- Revenue
- CLLS $49,217,000.00
- THRD N/A
- Revenue This Year
- CLLS $1.26
- THRD N/A
- Revenue Next Year
- CLLS N/A
- THRD N/A
- P/E Ratio
- CLLS N/A
- THRD N/A
- Revenue Growth
- CLLS 435.38
- THRD N/A
- 52 Week Low
- CLLS $1.14
- THRD $3.18
- 52 Week High
- CLLS $3.38
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- CLLS 38.55
- THRD 36.34
- Support Level
- CLLS $1.28
- THRD $3.41
- Resistance Level
- CLLS $1.35
- THRD $3.68
- Average True Range (ATR)
- CLLS 0.07
- THRD 0.14
- MACD
- CLLS 0.01
- THRD 0.09
- Stochastic Oscillator
- CLLS 38.46
- THRD 41.91
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.